EquiReason

EquiReason research coverage

10x Genomics, Inc. TXG

Healthcare · Health Information Services

24quarters analysed
12SEC filings read
6segments identified
13institutional managers tracked

Product lines it reports

The product and service lines 10x Genomics, Inc. breaks its revenue into.

  • Single Cell Consumables
  • Spatial Consumables
  • Licensing And Royalty Revenue
  • Spatial Instruments
  • Single Cell Instruments

Where its revenue is reported

The geographies 10x Genomics, Inc. reports revenue for. How much comes from each is in the product.

  • United States
  • EMEA
  • China
  • Asia Pacific Excluding China
  • Americas Excluding United States

What we read

The sources behind this company, and how many records of each we hold.

  • Financial statements27
  • Quarterly metric series12
  • Business segments6
  • SEC filings12
  • Insider transactions (Form 4)6
  • Institutional positions (13F)7
  • Earnings events1
  • Earnings quality checks5
  • Estimate revisions11
  • GAAP vs non-GAAP reconciliation1
  • Seasonal pattern6
  • Multi-period trajectory7
  • Inflection detection1
  • Fiscal calendar1
  • Index membership4

What we look for

Every company is run through the same checks. Both answers are reported — a signal we looked for and did not find is as much a fact as one we did.

  • Revenue series24
  • Margin series9
  • Cash flow series24
  • Earnings series24
  • Per-share series1
  • Operating cash flow series24
  • Guidance changesnot found

This page says how much of 10x Genomics, Inc. we have read. What any of it means — the direction, the dates, the evidence and what would overturn it — is inside the product.

Open TXG in EquiReason

This page publishes coverage counts and reported breakdown names, but no financial figures, price data, rankings or investment conclusions. Sources are SEC filings, earnings calls and public institutional disclosures. How the research is made · All companies

10x Genomics, Inc. (TXG) — research coverage | EquiReason